FDA Approves New Topical Treatment for Rosacea

Share this content:
FDA Approves New Topical Treatment for Rosacea
FDA Approves New Topical Treatment for Rosacea

(HealthDay News) -- A new prescription treatment for rosacea was approved on Monday by the U.S. Food and Drug Administration.

The FDA approved Bayer HealthCare's Finacea (azelaic acid) Foam, 15 percent, for topical treatment of mild to moderate rosacea, Bayer said in a news release. The approval is based on the results of two 12-week clinical trials that included 1,362 people, aged 19 to 92. The most common side effects of the foam were localized pain (6.2 percent of patients), pruritus (2.5 percent), dryness (0.7 percent), and erythema (0.7 percent).

There have been a few reports of hypopigmentation after the use of azelaic acid, and doctors should monitor patients with dark complexions for early signs of this problem, Bayer said. The company also cautioned that azelaic acid can irritate the eyes, and that Finacea Foam should not come into contact with the eyes, mouth, or other mucous membranes.

Finacea Foam will be available by prescription only beginning in September, according to Bayer.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

Doctors Remove Contact Lens Embedded in Eyelid for Years

Doctors Remove Contact Lens Embedded in Eyelid for ...

Lens was encapsulated within the upper eyelid soft tissue since childhood eye trauma

CDC: Brucellosis in Dogs Remains a Public Health Risk

CDC: Brucellosis in Dogs Remains a Public Health ...

Infection is under-recognized, may remain a threat without stronger intervention measures

is free, fast, and customized just for you!




Already a member?

Sign In Now »